- What we do
-
-
Routes of delivery
- Oral
- Nasal
- Pulmonary
- Parenteral
-
Development stage
- Pre-clinical
- Phase I to Phase II
- Phase III - Commercial
Our Approach
- Choosing Your CDMO Partner
- Project Management
-
- About us
-
-
A CDMO like no other
- About Us
- Our Facilities
- Our History
- Awards and Achievements
-
Leadership Expertise
- Executive Leadership Team
- Board of Directors
- Careers
-
-
- Resources
- Events
- Contact
Home / Resources / Whitepapers
Spray Drying Biologics: An Alternative To Freeze Drying

Drug products containing active biological ingredients form one of the most important and fastest-growing sectors of the pharmaceutical industry. The biologics market size is estimated to achieve sales of USD 429.5 billion in 2024 and is expected to reach 601.3 billion by 2029, growing at a CAGR of 6.96% between 2024-2029.
Dr. Richard Johnson, Chief Scientific Officer at Upperton Pharma Solutions discusses the growth and complexity of dosage forms containing biologics and the alternative drying technologies to traditional freeze drying technology.
Whitepaper Topics:
- The need for drying technologies to stabilise drug products containing biologics.
- Freeze drying: The established technology for producing dry powder biologics.
- Spray Drying: A viable, cost-effective alternative to freeze-drying.
- Creating stable dry powders whilst maintaining tertiary structure.
- Spray-drying complex liposomal formulations containing surface-encapsulated proteins and peptides.
Meet our experts

Dr. Richard Johnson
Chief Scientific Officer & Founder,
Upperton Pharma Solutions